Vincenti F, et al. - In de novo kidney transplant recipients receiving concomitant standard immunosuppression over 90 days posttransplant, safety, tolerability, pharmacokinetics, and pharmacodynamics of various doses of the anti-CD40 monoclonal antibody bleselumab were examined. Researchers randomly assigned 50 transplant recipients (1:1:1:1:1) to receive bleselumab 50 mg, 100 mg, 200 mg, or 500 mg, or placebo, in addition to standard maintenance immunosuppression. Their randomized treatment was received by 45 patients (bleselumab [n = 37] or placebo [n = 8]). In the range of 50–500 mg, they observed a more than dose-proportional increase in AUC_inf and AUC_last; a linear increase in C_max with increasing dose was observed. Bleselumab showed dose-dependent prolonged B-cell CD40 receptor occupancy and was well tolerated at all doses.